Medtronic has undertaken the international launch of its Resolute Onyx drug-eluting stent following the receipt of CE mark approval. The first live patient implant of the Resolute Onyx occurred during the XII International Course of Endovascular and Myocardial Therapy in Madrid, Spain.
Built on the proven clinical performance and superior deliverability of the Resolute Integrity drug-eluting stent, the Resolute Onyx is the first stent to feature a new advancement called CoreWire technology that allows it to have a denser core metal wrapped in a cobalt alloy outer layer. This new technology enables increased radiopacity and the Resolute Onyx has thinner struts to help improve deliverability without compromising radial and longitudinal strength.
The Resolute Onyx drug-eluting stent features a new delivery system with PowerTrac technology that was introduced earlier this year with the NC Euphora noncompliant balloon dilatation catheter. The advanced delivery system provides superior and enhanced deliverability through challenging lesions.
CoreWire technology is the next new drug-eluting stent advancement after continuous sinusoid technology, which was previously introduced with the Resolute Integrity drug-eluting stent and the Integrity bare-metal stent. Continuous sinusoid technology is a method of stent manufacturing that moulds one single strand of wire into a sinusoidal wave enabling a continuous range of motion.